APA (7th ed.) Citation

A, D., M, R., & GS, K. (2023). Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply. Alimentary pharmacology & therapeutics, 58(11-12), 1243. https://doi.org/10.1111/apt.17750

Chicago Style (17th ed.) Citation

A, Desai, Regueiro M, and Kochhar GS. "Letter: Tofacitinib, Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis-Authors' Reply." Alimentary Pharmacology & Therapeutics 58, no. 11-12 (2023): 1243. https://doi.org/10.1111/apt.17750.

MLA (9th ed.) Citation

A, Desai, et al. "Letter: Tofacitinib, Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis-Authors' Reply." Alimentary Pharmacology & Therapeutics, vol. 58, no. 11-12, 2023, p. 1243, https://doi.org/10.1111/apt.17750.